About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 426 record(s)
Req # A-2021-001147
Adverse Drug Reaction (ADR) for RILUZOLE. Report number: E2B_03720529.Organization: Health Canada
June 2022
Req # A-2021-001370
Adverse Drug Reaction (ADR) for [NAME]. Report number: E2B_03129948.Organization: Health Canada
June 2022
Req # A-2021-001417
Adverse Drug Reactions (ADRs). Report numbers: E2B_04369658, E2B_04433087, E2B_04430714, E2B_04314018, E2B_04365503, E2B_04419410, E2B_04429401, E2B_04423910, E2B_04436990, E2B_04455280, E2B_04454024, E2B_04470790, E2B_04429163, E2B_04402148.Organization: Health Canada
June 2022
Req # A-2021-001489
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_03833370, E2B_03835390, E2B_03832596, E2B_03839328, E2B_03872599, E2B_03842768, E2B_03840867, E2B_03841771, E2B_03850415, E2B_03847716, E2B_04003315, E2B_04003631, 000948910, E2B_03777804.Organization: Health Canada
June 2022
Req # A-2021-001510
Adverse Drug Reactions (ADRs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_03577231, E2B_03737998, E2B_03753504, E2B_03753498, E2B_03753493, E2B_03753481, E2B_03753477, E2B_03706150, E2B_03706080, E2B_03706149, E2B_03704205, E2B_03703430, E2B_03703468, E2B_04067082, E2B_03712527.Organization: Health Canada
June 2022
Req # A-2021-001515
Adverse Drug Reactions (ADRs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_03583020, E2B_03805504, E2B_03710825, E2B_03710800, E2B_03600204, 000936689, 000937179, 000928364, E2B_03706157, E2B_03706158, E2B_03706159, E2B_03706165, E2B_03709213, E2B_03548873.Organization: Health Canada
June 2022
Req # A-2021-001541
Adverse Drug Reaction (ADR) for ALLERGENIC EXTRACT - ALBUMIN SALINE WITH PHENOL. Report number: 000959909.Organization: Health Canada
June 2022
Req # A-2021-001628
Adverse Drug Reaction (ADR) for BUDESONIDE. Report number: E2B_04323333.Organization: Health Canada
June 2022
Req # A-2021-001675
Adverse Drug Reaction (ADR) for IPRATROPIUM BROMIDE. Report number: E2B_04133439.Organization: Health Canada
June 2022
Req # A-2021-001723
Adverse Drug Reactions (ADRs) for METFORMIN HYDROCHLORIDE. Report numbers: E2B_04458023, E2B_04122589, E2B_04181591, 000956566, 000961233, 000962239, 000955149, 000961005, E2B_04464691, 000969222, 000955170.Organization: Health Canada
June 2022